Shareholders approve Nanyang Biologics merger, surging RFAI

 

Shareholders approve Nanyang Biologics merger, surging RFAI 481% premarket

• EGM on Aug 19 approved all six proposals for business combination with Nanyang Biologics.
• Aug 20 SEC 8-K disclosed overwhelming vote results and ~3.96M share redemption requests.
• Nanyang is Singapore biotech focused on AI drug discovery; deal originated as $1.5B SPAC merger.
• Significant redemptions reduce float sharply, driving extreme volatility and price spike to ~$73 AH.
• RFAI closed regular session Aug 20 at $12.73 (up 13.7% intraday) before after-hours explosion.
• Confirms path to Nasdaq listing for combined company under expected ticker NYB.
• Low-float dynamics post-redemption amplified retail and momentum trading.

https://finviz.com/stock?t=RFAI&p=d